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ABSTRACT The cadherin superfamily of Ca2+-dependent homophilic adhesion molecules plays a
critical role in regulating cell-to-cell interactions. During development, the expression of different
cadherins is highly dynamic, since they are associated with the morphogenesis, establishment and/
or maintenance of different tissues. Alterations in cadherin expression or function occur frequently
during carcinogenesis, such as the loss of the epithelial cadherin (E-cadherin) and/or the aberrant
expression of other cadherins. Indeed, the aberrant expression of cadherins has been detected
during carcinoma invasion, a process which is reminiscent of the epithelial-mesenchymal transition
(EMT) so important in many critical developmental processes. The functional regulation of
cadherins can occur at many different levels, from transcriptional regulation to the control of the
strength of the cadherin-mediated cell-cell interaction. In this review, we will focus on the
transcriptional control of cadherin expression, both in development and carcinogenesis, paying
particular attention to the regulation of E-cadherin given its proposed role as a suppressor of
invasion. We will discuss the main genetic and epigenetic mechanisms involved in down-regulating
E-cadherin expression, and we will analyse the mechanisms involved in regulating EMT, in an
attempt to elucidate which elements are common to this process in both physiological and
pathological situations.
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Cadherins: a truly great family
The different cadherins constitute a superfamily of transmem-
brane receptors that mediate Ca2+-dependent cell-to-cell homophilic
interactions. Since the description of the first member of this
superfamily, uvomorulin (latter called E-cadherin), the cadherin
superfamily has grown to include more than 80 members in both
vertebrates and invertebrates (Nollet et al., 2000). The different
members of this superfamily can be organised into several sub-
families according to their structural and/or functional organisation
(Fig. 1). In this way, 5 different sub-families can be considered: 1)
Classical cadherins (type I), mainly localised to adherens junc-
tions; 2) Highly related type II cadherins; 3) Desmosomal cadherins
(desmocollins and desmogleins) that form desmosomal junctions;
4) Protocadherins, mainly implicated in neural development; 5)
Cadherin-related proteins, like the Flamingo and Fat-like cadherins
(Nollet et al., 2000).
In general terms, the structure of the cadherins is highly con-
served among the different members of the superfamily, particu-
larly in terms of the extracellular domain that is formed by different
numbers of the so-called cadherin domains (CD, or EC) (Takeichi,
1995). The classical cadherins present five cadherin domains
(EC1 to EC5) which are responsible for the homophilic interaction
of these molecules, especially the N-terminal EC1 domain. How-
ever, other sequences are also required for interactions between
cadherins of different subfamilies. The association of calcium ions
with a linker region connecting two of the EC domains induces the
conformational changes necessary for the extracellular domain of
cadherins to mediate their adhesive interactions. The cytoplasmic
domain of cadherins is also conserved within each subfamily, and
in the case of the classical cadherins, it is this domain that interacts
with catenins which link the cadherin to the actin cytoskeleton.
Although the extracellular domain is sufficient to mediate cell-cell
contacts, the cytoplasmic domain of cadherins is crucial to en-
hance the strength of this interaction and for cellular signaling.
An interesting discussion has arisen in recent years regarding
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the three dimensional distribution and interactions of cadherins. In
the accepted model, based on the crystal structure of the EC1-EC2
domain in the classical E- and N-cadherins, cadherins form dimers
in the cytoplasmic membrane by the cis-clustering of monomers
and lateral dimerisation. The cis-dimer expressed by adjacent cells
can therefore interact in trans, adopting the characteristic cadherin-
zipper structure that strengthens the adhesive junctions. However,
more recent data obtained from the crystal structure of the five EC
domains of C-cadherin has challenged the zipper model, suggest-
ing an alternative in which the EC1 to EC3 domains of each cis-
dimer are involved in the intercellular interactions (Boggon et al.,
2002).
Cadherin expression during development
During embryonic development, each member of the cadherin
superfamily exhibits its own specific spatio-temporal expression
pattern. The elegant pioneering studies of Takeichi on E- and N-
cadherin expression during mouse embryogenesis established a
critical role for cadherins as regulators of morphogenesis (Takeichi,
1988; 1995). Both E- and N-cadherin are considered as prototypic
cadherins in epithelial and mesenchymal tissues, respectively, and
they are involved in the regulation of morphological events such as
gastrulation, neurulation, cardiogenesis and somitogenesis. E-
cadherin is the first adhesion molecule expressed in the mouse
embryo, at the 8-cell stage, and is essential for the compaction of
the morula and the subsequent organisation of epithelial tissues.
Expression of E-cadherin is maintained in all epithelial tissues, but
it is silenced during the process of EMT and in established
mesenchymal cells (Takeichi, 1988; 1995). Loss of function stud-
ies (using functional antibodies, antisense nucleotides or transgenic
knock-out mice for E-cadherin) have demonstrated that E-cadherin
is crucial for early mouse development and the maintenance of
epithelial morphology (Larue et al., 1996). Similar studies on N-
cadherin have shown that it is required for cardiogenesis,
somitogenesis and the correct development of the nervous system
(Larue et al., 1996; Radice et al., 1997).
During early mouse development, dynamic and reciprocal
changes in E- and N-cadherin expression can be detected (known
as “cadherin switching”), for example when embryos undergo the
process of EMT at the primitive streak where a switch from E- to N-
cadherin expression occurs (Nakagawa and Takeichi, 1995).
However, the E- to N-cadherin switch is not a generalised event
when EMT occurs during development, and indeed it does not
occur during the emigration of the neural crest cells from the neural
tube in mouse embryos. Pre-migratory neural crest cells do not
express either E- or N-cadherin, but N-cadherin can be detected in
neural crest cells at their final destination (Takeichi, 1988; 1995).
In addition, although they are embryonic lethal, N-cadherin null
mutant mice are able to initiate gastrulation (Radice et al., 1997).
It has been suggested that other cadherins (such as cadherin-11
(OB-cadherin) and/or cadherin-6/6B) could be involved in the
regulation of cell-cell interactions in the absence of N-cadherin,
raising the hypothesis of partial functional substitution between
some cadherin members (Radice et al., 1997).
The expression of cadherins during EMT in other tissues has
also been examined, such as during the formation of the chick
neural crest. In these cells, L-CAM (liver-cell adhesion molecule,
the avian homologue of E-cadherin) is substituted by N-cadherin
and cadherin-6B during neural plate invagination (Nakagawa and
Takeichi, 1995). Furthermore, during migration of the chick neural
crest, no N-cadherin or cadherin-6B can be detected in these cells,
but rather they express cadherin-7 which is maintained until they
reach their appropriate destinations (Nakagawa and Takeichi,
1995). Similarly, cadherin switching has been observed in the
organisation of other embryonic tissues, supporting the suggestion
that N-cadherin is implicated in cell differentiation, segregation and
migration (Radice et al., 1997).
Cadherins are also involved in the developmental process that
is the inverse of EMT, Mesenchymal-Epithelial Transition (MET),
which occurs during events such as in kidney morphogenesis.
Indeed, cadherin-6 (K-cadherin) is the main adhesion molecule
involved in the conversion of mesenchymal cells into an epithelium
in the kidney. Studies with cadherin-6 deletion mutants have
confirmed that R-cadherin can compensate for the lack of cadherin-
6 during MET in the kidney, but in R-cadherin deficient mice this
process is barely affected (Dahl et al., 2002). Double knock-out
mice for R-cadherin and either P-cadherin, N-cadherin or cadherin-
6 show no substantial changes in phenotype when compared to the
single null mutants, suggesting that the regulation of cell-cell
contacts during MET in kidney cells is complex and involves the
participation of multiple cadherin molecules (Dahl et al., 2002).
Additionally, the atypical Ksp-cadherin (cadherin 16) is also in-
volved in epithelial kidney morphogenesis, this cadherin contains
a highly truncated cytoplasmic domain and is specifically ex-
pressed in renal tubular epithelial cells.
This overview of cadherin expression during developmental
processes indicates that the up- or down-regulation of specific
cadherin members is usually highly controlled and is associated
with the gain or loss of cell-cell adhesion. This suggests that control
of cadherin expression and function during EMT or MET might
involve at least two levels of regulation: 1) Control of cadherin
expression at the transcriptional level; and 2) Control of cadherin
function through signalling pathways that influence their stabilisation.
Cadherin expression during tumour progression
Modifications of cell-cell interactions similar to those observed
during development also occur in some pathological situations, such
as during carcinogenesis, where the disruption of cell-cell contacts is
one of the key events in tumour progression. During the last decade,
the expression of cadherins during tumour progression has been the
subject of extensive studies, the majority of which have focused on
the role of E-cadherin. The loss of E-cadherin expression and/or
function has been observed during tumour progression of most
carcinomas (reviewed in Takeichi, 1993; Birchmeier and Behrens,
1994), and this has been related to the induction of EMT which
frequently occurs during carcinoma invasion (Christofori and Semb,
1999; Thiery, 2002). These observations, together with data gath-
ered from other model systems, indicate that as initially proposed, E-
cadherin can be considered as an invasion suppressor gene
(Birchmeier and Behrens, 1994). Other cadherins have also been
implicated in tumour progression; for example, it has been proposed
that cadherin-13 (T-cadherin, H-cadherin) acts as a tumour suppres-
sor gene since its expression is significantly diminished in several
types of carcinomas. Silencing of cadherin-13 seems to occur by a
combination of allelic loss and promoter hypermethylation (Toyooka
et al., 2001). However, since cadherin-13 lacks the intercellular
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domain necessary for binding to cytoplasmic proteins and potential
signalling pathways, the molecular mechanisms by which it might act
as a tumour suppressor are still unclear.
Recent evidence has indicated that N-cadherin overexpression
can be correlated with an increase in the invasive potential of
breast cancer cells and that this induction appears to be correlated
with the decrease in the expression of other cadherins, such as E-
and P-cadherin in squamous cell carcinoma lines. This situation is
reminiscent of the E- to N-cadherin switching observed in some
developmental processes. Moreover, N-cadherin seems to have a
dominant effect, enhancing the motility of tumour cells even in
presence of E-cadherin in breast cancer cells (Nieman et al.,
1999). Neo-expression of N-cadherin has also been observed in
other tumour types, such as prostate (Tomita et al., 2000) and
intestinal gastric carcinomas (Rosivatz et al., 2002), suggesting a
functional role for this cadherin in cancer progression.
The increase in invasion and metastasis associated with N-
cadherin expression could be explained by a destabilisation of cell-
cell adhesion mediated by N-cadherin that allows the cells to
detach from the primary tumour and associate selectively with the
stroma and/or endothelium. Increased secretion of MMP-9 and
activation of the MAPK pathway after N-cadherin over-expression,
or the functional co-operation between N-cadherin and FGFR
signalling observed in breast cancer cells (Suyama et al., 2002),
could also account for the association between N-cadherin and
invasiveness. Nevertheless, while down-regulation of E-cadherin
expression is often correlated with EMT in many carcinoma cells,
over-expression of N-cadherin is not. Taken together, these obser-
vations suggest that aberrant expression of N-cadherin might play
an active role in tumour progression only in some specific carci-
noma cells or tumours.
Cadherin-11 is normally expressed in the brain, yet it has also
been proposed to be upregulated during tumour progression.
Several studies have reported over-expression of cadherin-11 in
breast and prostate cancer cell lines, and in some types of gastric
and prostate tumours including prostate metastatic lesions (Tomita
et al., 2000). Moreover, an increase in cadherin-11 expression is
frequently associated with the up-regulation of N-cadherin, sug-
gesting that rather than the loss of E-cadherin, the switching on of
both these cadherins could be important for the acquisition and/or
maintenance of an invasive and metastatic phenotype in specific
cancer cell types (Tomita et al., 2000).
Fig. 1. Organisation of the cadherin superfamily. The main structural and functional characteristics of the cadherin subfamilies and types are indicated.
Representative examples are shown, with gene denomination of some of them in brackets. The main structural domains and schematic structure of the
different cadherin types are shown at the right.
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The aberrant expression of other members of the cadherin
family has also been observed in carcinomas, as is the case for
cadherin-6 whose over-expression is correlated with malignancy in
renal cell carcinomas, independent of E-cadherin loss. Indeed, it
has been proposed that this molecule could be used as an
independent marker for the prognosis of tubular cell carcinomas.
Recently, N-cadherin and cadherin-8 have also been implicated in
the development and invasiveness of renal cell carcinomas. In
contrast, several studies on P-cadherin have shown that a de-
crease in the expression of this cadherin can be correlated with the
invasiveness of lung carcinoma and melanomas. However, a
recent study also revealed that a switch between E- and P-
cadherin expression might be involved in the progression from
Stage I to Stage II ovarian cancer (Patel et al., 2003). Moreover,
aberrant P-cadherin expression has been detected in several
carcinomas, including breast, cervical, oesophagus and basal cell
carcinomas.
In general, the cadherin switching that has been observed in
many tumours seems to be a mechanism to “make new friends”,
provoking a shift to a more dynamic adhesion state through the
expression of new cadherins. This change in the adhesion state
may allow tumour cells to migrate, as well as promoting interac-
tions with the stroma and endothelia. However, the mechanisms
underlying cadherin switching in development and cancer cur-
rently remain unclear. The heterogeneous pattern of switching
between several cadherin members observed in different types of
tumours and carcinoma cells suggest that environmental cues
and/or specific signalling pathways might underlie cadherin switch-
ing. All this information indicates that by elucidating the mechanism
that regulate the expression of distinct cadherin members in
Fig. 2. Schematic representation of the E-cadherin promoter region and E-box sequences in mouse, human and dog. (A) The E-cadherin promoter
region is represented with its representative proximal control elements in the proximal region (exerting either a positive or negative effect on E-cadherin
expression). The CAAT, GC and E-box1/E-box3 are conserved in all three promoters, while the E-box 2 is only present in the mouse promoter region. An
additional E-box (E-box 4) downstream of the transcription initiation site is present in the human promoter, but is not conserved in the region encompassing
the mouse promoter. Binding of identified factors to the different E-boxes is shown in the lower part. (B) Sequence of the E-boxes present in the proximal
region of the mouse, human and dog E-cadherin promoter. Observe the high degree of conservation of E-box 1 and E-box 3.
A
B
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different cancer types, we might obtain important clues to further
understand tumourigenesis.
Mechanisms of E-cadherin regulation during tumour
progression
Most of our current knowledge regarding the way in which
cadherin expression is controlled during tumour progression has
derived from studies on E-cadherin. Indeed, the involvement of E-
cadherin in epithelial morphogenesis and homeostasis, and its
proven anti-invasive role in carcinoma progression has fomented
interest in understanding the regulatory mechanisms that control
E-cadherin expression under normal and pathological circum-
stances.
The human E-cadherin gene (CDH1) is located at the 16q22.1
locus and is comprised of 16 exons, spanning 99 Kb of genomic
DNA. The mouse E-cadherin gene (cdh1) has a similar exon-intron
organisation and is located on chromosome 8. Loss of E-cadherin
function is thought to be one of the most important events during
carcinoma progression (Birchmeier and Behrens, 1994), an as-
sumption that is reinforced by the fact that germ line mutations in
CDH1 induce a predisposition to diffuse-type gastric cancer (see
Strathdee, 2002).
During tumour progression, E-cadherin can be functionally
inactivated by different mechanisms, including somatic mutation
and down-regulation of gene expression through promoter methy-
lation and/or transcriptional repression. Indeed, down-regulation
of the CDH1 gene expression is observed in many carcinomas
(Birchmeier and Behrens, 1994), while inactivating mutations,
frequent in diffuse gastric carcinomas and in lobular breast carci-
nomas, are rarely observed in other types of tumours (reviewed in
Berx et al., 1998; Strathdee, 2002). Indeed, the most frequent
genetic alterations of CDH1 in tumours involve exon-skipping and
out-of-frame mutations, and in most cases mutations occur in
combination with a loss of heterozygosity of the wild type allele
(Berx et al., 1998)
Epigenetic mechanisms of E-cadherin silencing
Anomalous hypermethylation of promoter CpG islands is an
important means of repressing tumour suppressor genes. DNA
methylation is known to be involved in the development of human
cancers, often characterised by a generalised hypomethylation of
DNA and local hypermethylation of CpG islands in the promoters
and upstream exons of many genes. The hypermethylation of CpG
islands is associated with the recruitment of methyl DNA binding
proteins (MBDs) and of histone deacetylase activity (HDACs),
which together contribute to the compaction of the DNA in the
promoter region and hence, to gene inactivation.
The initial studies on CDH1 promoter methylation not only
established a relationship between E-cadherin silencing and the
methylation of CpG islands in several carcinoma cell lines, but also
observed that treatment with 5-azacytidine re-activated E-cadherin
expression. Furthermore, methylation of the E-cadherin promoter
was observed in primary prostate and breast tumour lesions, in
contrast to normal adjacent tissues where it remained unmethylated.
Since these two pioneering studies, a large amount of data
regarding E-cadherin promoter methylation and tumour progres-
sion has been accumulated from a huge number of cell lines and
tumours (reviewed in Strathdee, 2002). Of particular interest was
the finding that in diffuse-type gastric cancer, methylation of the E-
cadherin promoter serves as a second hit to somatic or germ-line
genetic alterations in inactivating E-cadherin expression (Grady et
al., 2000). Indeed, it has also been proposed that methylation of E-
cadherin CpG islands can act as a second hit for transcriptional
repression to silence E-cadherin in ductal breast carcinoma (Cheng
et al., 2001).
The origin of abnormal E-cadherin promoter methylation is still
obscure. In the case of gastric cancer, exogenous agents like
oxygen species and H. pylori infection have recently been invoked
as the basis for ageing-related methylation in the stomach. In
support of this hypothesis, E-cadherin methylation has been con-
sidered as an early event in gastric carcinogenesis initiated by H.
pylori infection, and a progressive increase in E-cadherin methyla-
tion has been correlated with ageing. However, a relationship
between H. pylori infection and E-cadherin methylation during
ageing is still not clear (Tamura, 2002). Nevertheless, a series of
studies have suggested a relationship between viral oncogenesis
and aberrant methylation, as seen in Epstein Barr Virus (EBV)-
positive gastric carcinomas where the E-cadherin promoter, among
others, is hypermethylated (Kang et al., 2002).
Despite the loss of E-cadherin observed in primary carcinomas,
E-cadherin is frequently re-expressed at secondary metastatic foci
and even within lymph node metastasis. This indicates that E-
cadherin expression is dynamically regulated during tumour pro-
gression, a fact that apparently contradicts the assumed irrevers-
ibility of DNA methylation. Analysis of E-cadherin methylation in
breast carcinomas and in other tumour types has shown that
aberrant hypermethylation of CpG islands in the promoter region
of E-cadherin often occurs prior to invasion, indicating that it is an
early event in tumourigenesis. Moreover, hypermethylation of the
E-cadherin promoter seems to persist in invasive and metastatic
lesions in breast carcinomas, but with a rather heterogeneous
pattern between tumour cells. Additionally, dynamic changes in E-
cadherin methylation have been proposed to occur during tumour
progression (Graff et al., 2000). According to this model, tumour
cells with predominantly methylated E-cadherin alleles would be
responsible for the initiation of metastatic behaviour, but a de-
crease in methylation, leading to the re-expression of E-cadherin,
might occur in the established metastatic lesions and could contrib-
ute to survival of the cells in breast cancer. Indeed, re-expression
of E-cadherin in cells in the blood stream and secondary tissues
was earlier suggested as a general means for cancer cells to
survive (Takeichi, 1993). Whether dynamic E-cadherin methyla-
tion also occurs in other tumour types, thereby explaining changes
in E-cadherin expression during tumour progression, remains to be
established. On the other hand, methylation of the E-cadherin
promoter is not always correlated with E-cadherin silencing
(Strathdee, 2002), indicating that additional genetic or epigenetic
modifications might be required for E-cadherin down-regulation.The
molecular mechanisms involved in regulating E-cadherin methyla-
tion are starting to be unravelled. Recently, the association of
several MBDs, such as MeCP2, MBD1 and MBD2, with the E-
cadherin promoter have been reported in several cancer cell lines
(Koizume et al., 2002). Interestingly, methylation of E-cadherin
CpG islands and MeCP2 expression have been shown to co-
operatively and epigenetically regulate E-cadherin expression in
colorectal cancer cells (Darwanto et al., 2003). It is also possible
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that other epigenetic mechanisms, like histone deacetylation,
participate in regulating E-cadherin expression. Histone H3
deacetylation is associated with CpG methylation-mediated gene
silencing in other contexts and recently, the participation of both
epigenetic modifications was reported for E-cadherin down-regu-
lation in several cancer cell lines (Koizume et al., 2002).
Transcriptional regulation of E-cadherin silencing
Besides regulation of E-cadherin by promoter hypermethylation
and/or genetic alterations, direct transcriptional control of E-cadherin
has emerged in the last years as an important regulatory mecha-
nism of E-cadherin expression. The mouse E-cadherin promoter
was first isolated in 1991. Its initial characterisation showed it was
a TATA-less promoter containing several potential proximal regu-
latory elements, including a CCAAT box (-65), a GC-rich region (-
30 to -58) and a palindromic element (-70 to –90) composed of two
adjacent E-boxes flanked by four inverted nucleotides called ‘E-
pal’ (Behrens et al., 1991). The proximal CCAAT and GC-rich
regions are required for basal E-cadherin expression and are
recognised by constitutive AP2 and Sp1 transcription factors, and
CAAT-binding proteins, respectively (Behrens et al., 1991; Hennig
et al., 1996; Faraldo et al., 1997). The E-pal element was initially
described as an epithelial-specific regulator (Behrens et al., 1991),
but subsequent studies showed it to be an active repressor in E-
cadherin deficient cells (Hennig et al., 1996; Faraldo et al., 1997;
Rodrigo et al., 1999). In addition, an epithelial-specific enhancer
does exist in the first intron of the mouse E-cadherin gene, which
is recognised by AP2 factors and other potential regulators (Hennig
et al., 1996). An additional regulatory element, containing Ets-
binding sites, has also been described in the mouse promoter and
may contribute to the repression of E-cadherin expression (Rodrigo
et al., 1999).
A comparison of the human, mouse and dog E-cadherin pro-
moters (Comijn et al., 2001) showed that the CAAT-box and GC-
rich regions are conserved at similar locations (see Fig. 2). The
proximal E-box in the mouse E-pal element is also conserved in the
human and dog promoters, as is the additional E-box (E-box 3)
located at -30 in all promoters. However, the additional E-box (E-
box 4) downstream of the transcription initiation site in the human
promoter (Batlle et al., 2000) is not present in the mouse promoter.
Several studies have demonstrated that the E-boxes in the
proximal E-cadherin promoter repress its expression. Point muta-
tions abolishing the two E-boxes in the mouse E-pal, or E-box 1 and
3 in the human promoter, produced a strong induction of E-cadherin
promoter activity in different carcinoma cell lines deficient in E-
cadherin expression. Evidence has also been presented that the E-
box 4 also represses E-cadherin expression (Batlle et al., 2000; Hajra
et al., 2002), hence, factors able to bind to the E-boxes and repress
E-cadherin expression must be present in these cells. In vivo analysis
of the endogenous human and mouse E-cadherin promoter by
footprinting supports this hypothesis. The E-pal or E-box 1 were
specifically protected in E-cadherin deficient cells, as well as in
several dedifferentiated carcinoma cell lines and fibroblasts (Hennig
et al., 1996; Rodrigo et al., 1999). An important concept derived from
such studies was that the repressors bound to proximal E-boxes
were able to overcome the positive effects of constitutive factors
interacting with the basal regulatory elements of the E-cadherin
promoter, such as AP2 and Sp1 (Rodrigo et al., 1999).
Characterisation of E-cadherin repressors
A major breakthrough in understanding the regulation of E-
cadherin transcription has been the identification of several E-
cadherin repressors. Using an approach based on the yeast one-
hybrid system, we searched a cDNA library from E-cadherin
deficient NIH3T3 fibroblasts for repressors binding to the E-boxes
in the E-pal element of the mouse E-cadherin promoter. The
specificity of the factors identified was confirmed in a parallel
screen with an E-pal element in which a point mutation abolished
the repressor function (Hennig et al., 1996; Faraldo et al., 1997)
and which should also preclude the binding of regulatory factors.
More than 90% of the identified factors that specifically bound to the
E-boxes corresponded to transcription factors, of which, two in
particular were highly represented: 49% corresponded to the zinc
finger factor Snail and 32% to the class I bHLH factors, E47 (Cano
et al., 2000; Pérez-Moreno et al., 2001). The remaining factors
corresponded mainly to an additional class I bHLH factor, mITF2
(also called E2-2; F. Portillo, L. Holt and A. Cano, unpublished),
while a single clone corresponded to another member of the Snail
family, Slug (Bolós et al., 2003).
Functional characterisation of Snail indicated that it does indeed
act as a strong repressor of the mouse and human E-cadherin
promoters (Batlle et al., 2000; Cano et al., 2000). Snail repressor
activity is strictly dependent on the intact E-pal element in the
mouse promoter (Cano et al., 2000), but it apparently requires the
three E-boxes of the human promoter (Batlle et al., 2000). Impor-
tantly, overexpression of Snail in epithelial cells produces a dra-
matic EMT, and the acquisition of migratory and in vitro invasive
behaviour (Cano et al., 2000). Consistent with this behaviour, Snail
and E-cadherin expression is inversely correlated in different
mouse and human carcinoma and melanoma cell lines (Batlle et
al., 2000; Cano et al., 2000; Poser et al., 2001). Initial studies of
Snail expression in primary mouse skin carcinomas showed that it
is specifically expressed in invasive areas, coinciding with the
down-regulation of E-cadherin expression (Cano et al., 2000), thus
strongly supporting the involvement of Snail in E-cadherin repres-
sion at the invasive front. Recent studies in breast carcinoma
biopsies have highlighted the association between Snail expres-
sion, dedifferentiation and lymph-node status of ductal breast
carcinomas (Cheng et al., 2001; Blanco et al., 2002). Similar
observations have also been made recently in invasive hepatocel-
lular carcinomas (Sugimachi et al., 2003). In breast carcinomas,
Snail expression could be observed in a subset of ductal tumours
without positive lymph nodes, suggesting its potential utility as an
early prognostic marker of malignancy (Blanco et al., 2002).
The functional characterisation of bHLH E47 and Slug has also
confirmed the ability of both factors to behave as E-cadherin
repressors and to induce EMT when over-expressed in epithelial
cell lines (Pérez-Moreno et al., 2001; Bolós et al., 2003). Moreover,
the repression of human E-cadherin by Slug in breast carcinoma
cell lines has also been reported (Hajra et al., 2002). In addition,
while evidence accumulates that mITF2 can also behave as an E-
cadherin repressor (Holt et al., in preparation), two factors of the
homeodomain and zinc finger family, δEF1(Zeb1) and SIP1(Zeb2)
have also been described as repressors of E-cadherin (Grooteclaes
and Frisch, 2000; Comijn et al., 2001). In all these instances, these
repressors silence E-cadherin by binding to the proximal E-boxes,
although some differences are observed between the mouse and
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human promoters. While the factors that act on the mouse pro-
moter seem to preferentially interact with the E-pal element (includ-
ing Snail, Slug and E47: Cano et al., 2000; Pérez-Moreno et al.,
2001; Bolós et al., 2003), in the human promoter either all three E-
boxes or E-box 1 and 3 appear to be required for the interaction of
Snail/Slug or δEF1/SIP1, respectively (Batlle et al., 2000;
Grooteclaes and Frisch, 2000; Comijn et al., 2001; Hajra et al.,
2002). These observations suggest that at least two of the three
proximal E-boxes in the mammalian E-cadherin promoter are
functionally similar in terms of recruiting repressors, regardless of
their relative location. Interestingly, all of the E-cadherin repressors
identified exhibit expression patterns in developing embryos com-
patible with this function (see below).
and E47, revealed that Snail binds with a higher affinity than the
other two repressors. The affinity constant of Snail binding to the
E-pal (0.5 nM) is one and two orders of magnitude higher than that
of E47 and Slug, respectively (Bolós et al., 2003). This indicates
that a hierarchy might exist in terms of the participation of the three
repressors when present in the same biological context: Snail will
predominate over E47, which in turn will predominate over Slug in
silencing E-cadherin. An analysis of the expression of the different
repressors in tumour biopsies should clarify the specific participa-
tion of each factor in down-regulating E-cadherin. In this regard, a
recent study in gastric carcinomas has shown an association
between E-cadherin repression and Snail expression in diffuse
gastric carcinomas while SIP1 expression was linked to E-cadherin
Fig. 3. A model for the regulation of E-cadherin expression involving different repressors and
epigenetic mechanisms. A schematic illustration of the putative epigenetic mechanisms involved
in E-cadherin regulation is shown. In this model, active transcription is probably achieved through
the interaction of several activators, and involves the actetylation of histone residues which
promotes the chromatin to adopt an open conformation. Under the influence of the appropriate
signals, several repressors and co-repressor molecules are recruited (depending on either the tissue
or cellular context), attracting the repressor machinery which includes corepressor molecules,
HDACs and methylases, and still unidentified molecules which will modify the acetylation and
methylation status of chromatin, promoting E-cadherin silencing (see text for details).
Co-operation of the different repres-
sors or a functional hierarchy in E-
cadherin down-regulation?
One important question that remains
unresolved when considering the transcrip-
tional repression of E-cadherin relates to
the specific participation of the different re-
pressors in the down-regulation of E-
cadherin during tumour progression.
Analysing the expression of different re-
pressors in several carcinoma cell lines has
rendered some apparently contradictory
results. Thus, in a panel of breast carcinoma
cell lines, the inverse correlation between
Slug expression and E-cadherin down-regu-
lation was stronger than with Snail expres-
sion, suggesting that in vivo Slug may be a
more likely repressor of E-cadherin in breast
cancer (Hajra et al., 2002). In contrast, when
primary ductal breast carcinomas were
analysed, Snail appeared to be the candi-
date repressor of E-cadherin expression
(Cheng et al., 2001; Blanco et al., 2002).
Similarly, Snail was associated with the
down-regulation of E-cadherin in invasive
hepatocarcinomas (Sugimachi et al., 2003),
while other studies showed that E-cadherin
down-regulation was associated with the
co-expression of Snail and SIP1, or the
preferential expression of SIP1 in different
carcinoma cell lines (Comijn et al., 2001).
Interestingly, an inverse correlation between
E-cadherin and δEF1 (associated with Snail
expression) but not with SIP1 has also been
observed (Guaita et al., 2002). Furthermore,
in several carcinoma and melanoma cell
lines the inverse expression of E12/E47 and
E-cadherin has been reported (Pérez-
Moreno et al., 2001).
Some insights into the role of the different
E-cadherin repressors have been obtained
from in vitro studies. A comparative analysis
of the binding affinities for the E-pal element
of three E-cadherin repressors, Snail, Slug
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repression in intestinal type gastric carcinomas (Rosivatz et al.,
2002). Although still preliminary, these data indicate that the
different repressors may participate in silencing E-cadherin specifi-
cally in different types of tumour or, perhaps, at defined stages of
tumour progression. A more detailed analysis of the expression of
these repressors in large-scale tumour samples is clearly needed
to study this hypothesis, an aim that is presently hindered by the
lack of good specific antibodies to the different repressors.
Mechanism of E-cadherin repression: potential co-op-
eration with epigenetic modifications
The information available regarding the different mechanisms
involved in E-cadherin silencing make it difficult to define a simple
model where E-cadherin expression is regulated by just a single
genetic, epigenetic or transcriptional control mechanism. It seems
more likely that a combination of different mechanisms is respon-
sible for defining the status of E-cadherin expression during tumour
progression. As such, a modification of the classical “two hit
hypothesis” for E-cadherin silencing has recently been proposed
by Cheng et al., in which a collaboration between genetic, epige-
netic and transcriptional control of E-cadherin expression is at play
in ductal breast cancer (Cheng et al., 2001). In this system Snail
expression is correlated with the silencing of E-cadherin and
hypermethylation of its promoter, rather than by methylation itself.
Indeed, one interpretation of this model might invoke an interesting
role for Snail in the co-ordination of both processes (Cheng et al.,
2001).
The specific mechanisms by which Snail, and/or other repres-
sors, mediates E-cadherin silencing are still largely unknown. The
modification of chromatin by the co-ordinated action of DNA and/
or histone methylation, and acetylation, has emerged as one of the
major mechanisms for regulating the transcriptional activity of
different regulatory genes. Indeed, several years ago the modifica-
tion of chromatin was proposed as a mechanisms to regulate E-
cadherin expression, and the participation of histone deacetylase
activities (HDACs) has been used to explain the repressor activity
of human Slug on artificial promoters (Hemavathy et al., 2000).
Very recently, details of the mechanism underlying Snail repres-
sion of E-cadherin were revealed, providing a link between tran-
scriptional control and the epigenetic modifications of the E-
cadherin promoter (Peinado et al., 2004). Snail repression of the E-
cadherin promoter involves the recruitment of a repressor complex
formed, at least, by the co-repressor mSin3A, HDAC1 and HDAC2
(Peinado et al., 2004) (Fig. 3). The recruitment of this complex is
mediated by the N-terminal SNAG domain of Snail, previously
thought to act as the repressor domain. The presence of this
complex results in a net decrease in the amount of acetylated
histones H3/H4 and an increase in methylated K9 of histone H3 in
the endogenous E-cadherin promoter. In turn, this leads to a
compact organisation of the chromatin (Peinado et al., 2004). A
preliminary analysis in the mouse skin carcinogenesis model
indicates that Snail expression is also associated with the
hypermethylation and silencing of the E-cadherin promoter, further
supporting the notion of a connection between Snail and epigenetic
modifications (Fraga, M., Peinado, H. et al., in preparation; see Fig.
3). The molecular mechanisms involved in this link remain to be
elucidated, but the implication of MBDs and HDACs is an interest-
ing aspect of E-cadherin silencing for further study, since treatment
with inhibitors of DNA methylation and HDACs promotes the re-
expression of E-cadherin (Peinado et al., 2004, and unpublished
results).
The molecular mechanisms responsible for Slug repression
remain to be established. Nevertheless, it is worth bearing in mind
that apart from the N-terminal SNAG domain, Slug contains a
partially conserved domain that interacts with the CtBP co-repres-
sor (Hemavathy et al., 2000), opening the possibility for Slug to co-
operate with different repressor complexes. CtBP interacting do-
mains (CID) are present in the homeodomain-zinc binding factors
δEF1 and SIP1, and an interaction with CID was previously
reported to be necessary for δEF1 to effectively repress the E-
cadherin promoter (Grooteclaes and Frisch, 2000). The recent
Fig. 4. Model of the participation of different E-
cadherin repressors during tumour invasion. In this
model, several repressors like Snail and SIP1 would play
a role in the first step of tumour progression leading to
the initiation of the invasive process through the down-
regulation of E-cadherin and other epithelial markers,
and the induction of mesenchymal markers which pro-
mote invasion. Other repressors, like Slug or E-47, may contribute to the maintenance of the malignant phenotype by sustained E-cadherin repression and
promoting ECM degradation and cell motility, provoking the appearance of isolated cells capable of eventually undergoing metastasis (see text for details).
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isolation of a CtBP co-repressor complex containing different
methylase and HDAC activities, as well as the δEF1 and SIP1
factors, and which is functionally active on E-cadherin promoter
regulation (Shi et al., 2003), strongly support the participation of
CtBP complexes in down-regulating E-cadherin expression (Fig.
3). Whether δEF1 and SIP1 factors do indeed play a direct or
indirect role in the CtBP repressor complex remains to be estab-
lished.
The mechanisms involved in E47-mediated repression of E-
cadherin are still unknown. In contrast to Snail and Slug, prelimi-
nary analyses do not suggest that HDAC activity is involved but
rather point to a regulatory mechanism involving heterodimerisation
with either the class II bHLH factors, such as Twist, or Id regulators
(E. Cubillo, H. Peinado, and A. Cano, unpublished).
In summary, current evidence indicates that silencing of E-
cadherin transcription requires the participation of several repres-
sor factors that interact with specific E-boxes in the proximal
promoter. The repression of gene expression either involves the
local modification of chromatin organisation through the recruit-
ment of specific co-repressor complexes (Snail, Slug and poten-
tially δEF1/SIP1), or heterodimerisation of repressors with specific
partners (E47). These mechanisms of repression add an additional
level of complexity to our understanding of the different factors that
specifically repress E-cadherin expression. Thus, as well as the
specific expression patterns and/or binding affinities for similar
regulatory elements, repressor function might finally be regulated
by the presence of, and/or affinity for, different co-repressors in
specific cells or tissues. Thus, the regulation of expression and
function of the different repressors needs also to be taken into
account to obtain a comprehensive view of the transcriptional
control of E-cadherin. In this sense, a recent study has elegantly
shown that silencing of Snail expression can be triggered by the
ligated oestrogen receptor in breast cancer cell lines, involving the
specific participation of the MTA3 protein in an additional repressor
complex (Fujita et al., 2003). In this system, Snail expression is de-
repressed by a deficiency in oestrogen receptors or in the MTA3
protein, producing the suppression of E-cadherin expression (Fujita
et al., 2003).
Interestingly, epigenetic modifications of the Snail promoter
also seem to be involved in the regulation of its expression during
mouse skin tumour progression (Fraga, M., Peinado, H. et al., in
preparation). This indicates that several co-repressor molecules
and epigenetic mechanisms might also regulate the expression of
epithelial and mesenchymal genes. Furthermore, Snail expression
is induced by activated ILK (Tan et al., 2001) and by TGFβ, and/or
oncogenic H-ras signals in epithelial cells (Peinado et al., 2003),
and the nuclear localisation of Snail also seems to be under fine
control (Dominguez et al., 2003). This information points to other
important mechanisms that might influence the expression of E-
cadherin via external signals during tumour progression.
Mechanisms underlying the regulation of other cadherin genes,
or cadherin switching during tumour progression are poorly under-
stood. A few additional cadherin promoters have been characterised,
like P-, N- and Ksp-cadherin. All of them are TATA-less promoters
and contain conserved CCAAT and GC-rich regions, as well as
several E-boxes, with the exception of P-cadherin (Faraldo et al.,
1997; Li et al., 1997; Whyte et al., 1999). Although some regulatory
elements that confer tissue specific expression have been de-
scribed in these promoters, potential elements responsible for
activation or repression during tumourigenesis remain to be dis-
covered. However, it is tempting to speculate that some of the E-
cadherin repressors identified could also work as activators of
other cadherin genes, as well as of mesenchymal genes.
Regulatory mechanisms of E-cadherin expression in
development. What can we learn about the role of
repressors?
As discussed above, E-cadherin is expressed in a highly dy-
namic fashion during early mouse development. It is present in all
epithelial cells from the early morula stage but disappears in cells
undergoing EMT or in established mesodermal cells (Takeichi,
1988; 1995). The mechanisms regulating E-cadherin expression
during development are still poorly understood. Intriguingly, a
recent study was unable to find proximal upstream or downstream
regulatory elements that might be responsible for the tissue speci-
ficity of E-cadherin expression, suggesting a major role for down-
stream tissue-specific enhancer elements (Stemmler et al., 2003).
Similar studies on other cadherins suggest that the tissue specific
transcriptional regulation of widely expressed cadherin members,
like N-cadherin, is highly complex in vivo, probably involving
different enhancer-specific regulators (Li et al., 1997). In contrast,
the tissue specific regulation of cadherins whose expression is
more restricted, like Ksp-cadherin in tubular kidney cells, is pro-
vided by proximal elements (Whyte et al., 1999).
Despite the lack of information on cadherin regulation in vivo, we
now have a more comprehensive knowledge of the role of E-
cadherin repressors in development. Snail family members are
now recognised as important regulators of EMT during early
vertebrate development (Nieto, 2002). Indeed, in mouse develop-
ment the expression pattern of Snail is closely correlated with the
down-regulation of E-cadherin expression in regions where EMT
occurs, while Slug expression is observed in the already migratory
mesenchymal cells (Cano et al., 2000; Nieto, 2002). The pattern of
E2A expression (encoding E12/E47 factors), and of E2-2 (encod-
ing mITF2), is similar to that of Slug (Pérez-Moreno et al., 2001);
Holt et al., unpublished). On the other hand, Zfhx1b (encoding
SIP1) is expressed in the neuroepithelium and both the premigra-
tory and migratory neural crest cells of specific regions, as well as
in the branchial arch mesoderm (van de Putte et al., 2003).
Therefore, the developmental expression patterns of known re-
pressors of E-cadherin are fully consistent with their repressor role
in epithelial cell systems.
Analysis of Snail knock-out embryos has provided compelling
evidence for its role as a repressor of E-cadherin in EMT. Snail null
mice present early embryonic lethality, and they fail to complete
gastrulation, giving rise to a deficient mesodermal layer in which E-
cadherin expression is maintained. In contrast, Slug null mice are
viable, undergoing an apparently normal program of mesoderm
and neural crest cell development (see Nieto, 2002). The absence
of mesoderm and neural crest defects have also been observed in
null mice for the E2A or E2-2A gene, and these phenotypes have
been explained by the potentially redundant role of the class I bHLH
factors encoded by both genes (E12/E47 and E2-2A/E2-2B, re-
spectively). On the other hand, the Zfhx1b knock-out mice are
embryonic lethal at 9.5 dpc, and they exhibit several defects in
neural crest migration or specification. Specifically, these mice are
deficient in post-mitotic vagal neural crest, display defects in
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cranial neural crest delamination and exhibit ectopic E-cadherin
expression in the neuroepithelium (van de Putte et al., 2003).
The distinct expression patterns observed between the different
E-cadherin repressors during development and their null pheno-
types, suggest a hierarchy of these factors. Thus we can envisage
a prominent role for Snail in inducing EMT, a more restricted role
for SIP1 in migration and specification of distinct neural crest cell
populations, and a role for Slug and E12/E47 (and E2-2 products)
in the maintenance of the mesoderm. These developmental analy-
ses strongly support the idea that the regulation of E-cadherin
expression is similar during normal development and tumour
progression (Cano et al., 2000), and support the specific and
hierarchical participation of the different factors in the repression of
E-cadherin during invasion.
Based on the available information we propose a model for the
participation of the different E-cadherin repressors in tumour
invasion (Fig. 4). Thus, the transient expression of Snail, or SIP1,
will be involved in inducing the invasion process, with perhaps the
more specific participation of each repressor in distinct types of
carcinomas. In contrast, other repressors, such as Slug, E47 and
perhaps δEF1, will be involved in the maintenance of the migratory
invasive phenotype. Curiously, this model also fits with the relative
binding affinities of some of the repressors (Snail, Slug and E47)
as determined in vitro for the regulatory E-boxes, and could also
explain some of the apparent discrepancies found in the literature.
Indeed, it may become apparent that the breast carcinoma cell
lines used in different analyses represent distinct stages of tumour
progression and/or invasiveness and, therefore, the expression
patterns of the different repressors observed, such as Snail and
Slug or SIP1, could reflect their distinct origins. In other words, we
need to think of tumour invasion as a highly dynamic process,
similar to EMT in development, whereas we have probably so far
only been looking at still images.
Although the information gathered so far has been instrumental
to increase our understanding of how E-cadherin expression and
tumour progression are regulated, a closer view of similar develop-
mental processes, together with a large scale analysis of tumour
biopsies, will certainly help to increase our understanding of the
tumour invasion process. This will in turn contribute to the design
of new therapeutic approaches based on the inhibition of the
expression and/or function of E-cadherin repressors.
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